Multidisciplinary Clinical Research Center in Musculoskeletal Diseases, The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
Department of Orthopaedics, University of Utah, Salt Lake City, UT 84158, USA.
Spine J. 2018 Apr;18(4):584-592. doi: 10.1016/j.spinee.2017.08.246. Epub 2017 Aug 25.
Minimally invasive lumbar spinal stenosis procedures have uncertain long-term value.
This study sought to characterize factors affecting the long-term cost-effectiveness of such procedures using interspinous spacer devices ("spacers") relative to decompression surgery as a case study.
Model-based cost-effectiveness analysis.
The Medicare Provider Analysis and Review database for the years 2005-2009 was used to model a group of 65-year-old patients with spinal stenosis who had no previous spine surgery and no contraindications to decompression surgery.
Costs, quality-adjusted life years (QALYs), and cost per QALY gained were the outcome measures.
A Markov model tracked health utility and costs over 10 years for a 65-year-old cohort under three care strategies: conservative care, spacer surgery, and decompression surgery. Incremental cost-effectiveness ratios (ICER) reported as cost per QALY gained included direct medical costsfor surgery. Medicare claims data were used to estimate complication rates, reoperation, and related costs within 3 years. Utilities and long-term reoperation rates for decompression were derived frompublished studies. Spacer failure requiring reoperation beyond 3 years and post-spacer health utilities are uncertain and were evaluated through sensitivity analyses. In the base-case, the spacer failure rate was held constant for years 4-10 (cumulative failure: 47%). In a "worst-case" analysis, the 10-year cumulative reoperation rate was increased steeply (to 90%). Threshold analyses were performed to determine the impact of failure and post-spacer health utility on the cost-effectiveness of spacer surgery.
The spacer strategy had an ICER of $89,500/QALY gained under base-case assumptions, and remained under $100,000 as long as the 10-year cumulative probability of reoperation did not exceed 54%. Under worst-case assumptions, the spacer ICER was $482,000/QALY and fell below $100,000 only if post-spacer utility was 0.01 greater than post-decompression utility or the cost of spacer surgery was $1,600 less than the cost of decompression surgery.
Spacers may provide a reasonably cost-effective initial treatment option for patients with lumbar spinal stenosis. Their value is expected to improve if procedure costs are lower in outpatient settings where these procedures are increasingly being performed. Decision analysis is useful for characterizing the long-term cost-effectiveness potential for minimally invasive spinal stenosis treatments and highlights the importance of complication rates and prospective health utility assessment.
微创腰椎狭窄手术的长期价值不确定。
本研究旨在通过使用棘突间间隔器(“间隔器”)作为减压手术的病例研究,对影响此类手术长期成本效益的因素进行特征描述。
基于模型的成本效益分析。
使用 2005 年至 2009 年的 Medicare Provider Analysis and Review 数据库,对没有接受过脊柱手术且无减压手术禁忌证的 65 岁脊柱狭窄患者进行建模。
成本、质量调整生命年(QALY)和每获得一个 QALY 的成本是结果测量指标。
一项 Markov 模型对三种治疗方案下 65 岁队列的健康效用和成本进行了 10 年的跟踪:保守治疗、间隔器手术和减压手术。报告的增量成本效益比(ICER)为每获得一个 QALY 的成本,包括手术的直接医疗成本。使用医疗保险索赔数据来估计 3 年内的并发症发生率、再次手术和相关成本。减压手术的长期再手术率和效用来源于已发表的研究。间隔器失效需要在 3 年后再次手术以及间隔器后健康效用是不确定的,并通过敏感性分析进行了评估。在基本情况下,间隔器的失效率在第 4 年至第 10 年保持不变(累计失效率:47%)。在最坏情况下分析中,10 年累计再手术率急剧增加(达到 90%)。进行了阈值分析以确定失效和间隔器后健康效用对间隔器手术成本效益的影响。
在基本情况下,间隔器策略的每获得一个 QALY 的成本效益比为 89500 美元,只要 10 年累计再手术概率不超过 54%,该成本效益比就保持在 100000 美元以下。在最坏情况下,间隔器的 ICER 为 482000 美元/QALY,只有在间隔器后效用比减压后效用高 0.01 或间隔器手术成本比减压手术成本低 1600 美元时,成本效益比才会低于 100000 美元。
对于腰椎管狭窄症患者,间隔器可能是一种具有合理成本效益的初始治疗选择。如果这些手术在门诊环境中进行,手术成本更低,那么它们的价值预计会提高。决策分析有助于描述微创脊柱狭窄治疗的长期成本效益潜力,并强调了并发症发生率和前瞻性健康效用评估的重要性。